Menu Search
Equities

ReShape Lifesciences Inc

RSLS:NAQ

ReShape Lifesciences Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.112
  • Today's Change-0.013 / -10.11%
  • Shares traded2.48m
  • 1 Year change-83.39%
  • Beta1.4476
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ReShape Lifesciences Inc had revenues fall -22.79% from 11.24m to 8.68m, though the company grew net income from a loss of 46.21m to a smaller loss of 11.39m.
Gross margin67.47%
Net profit margin-112.11%
Operating margin-119.44%
Return on assets-98.88%
Return on equity-184.59%
Return on investment-169.55%
More ▼

Cash flow in USDView more

In 2023, ReShape Lifesciences Inc increased its cash reserves by 15.27%, or 604.00k. Cash Flow from Financing totalled 17.57m or 202.51% of revenues. In addition the company used 16.96m for operations while cash used for investing totalled 10.00k.
Cash flow per share-0.5302
Price/Cash flow per share--
Book value per share0.1033
Tangible book value per share0.1033
More ▼

Balance sheet in USDView more

ReShape Lifesciences Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio1.90
Quick ratio0.8875
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.